$68.18
Price
$8.1B
Market Cap
23.9
P/E Ratio
6.9
Forward P/E
$2.85
EPS (TTM)
—
Dividend Yield
$319M
Cash
$2.1B
Total Debt
119M
Shares Out
$51.06
$82.22
52-Week Range
Institutional Ownership of HALOZYME THERAPEUTICS INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for HALOZYME THERAPEUTICS INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| No activity found for this stock. | |||||
Insider Trading for HALOZYME THERAPEUTICS INC
6 Months Insider Sentiment
Buy $0
Sell $1.3M
0
Buys
6
Sells
-1.3M
Net
1
Grants
Largest
$713K
Torley
$375K
Torley
$140K
Connaughton
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 05, 2026 | Bernadette Connaughton | Director | SELL | 2.0K | $70.25 | $140K |
| Jan 03, 2026 | Mark Howard Snyder | SVP, CHIEF LEGAL OFFICER | EXERCISE | 7.6K | — | — |
| Jan 02, 2026 | James Paul Lang | Director | GRANT | 889 | — | — |
| Dec 01, 2025 | Bernadette Connaughton | Director | SELL | 829 | $71.60 | $59K |
| Dec 01, 2025 | Helen Torley | PRESIDENT AND CEO | SELL | 5.4K | $69.44 | $375K |
| Dec 01, 2025 | Helen Torley | PRESIDENT AND CEO | SELL | 10.4K | $68.51 | $713K |
| Dec 01, 2025 | Helen Torley | PRESIDENT AND CEO | SELL | 500 | $70.36 | $35K |
| Dec 01, 2025 | Helen Torley | PRESIDENT AND CEO | EXERCISE | 16.6K | $8.11 | $134K |
| Dec 01, 2025 | Helen Torley | PRESIDENT AND CEO | SELL | 261 | $71.60 | $19K |